Trump signs order fast tracking review of psychedelics for mental health disorders

April 18, 2026 - 17:31

In a move signaling a significant shift in federal drug policy, an executive order has been signed to fast-track the scientific and medical review of certain psychedelic compounds for the treatment of mental health disorders. The directive specifically mandates agencies to examine the potential of substances like psilocybin, found in "magic mushrooms," and ibogaine, a plant-derived compound, for conditions including severe depression, post-traumatic stress disorder (PTSD), and substance abuse disorders.

This action aims to cut bureaucratic red tape, compelling health officials to prioritize the evaluation of these currently Schedule I drugs. The order frames this as a critical step in addressing the nation's ongoing mental health crisis, seeking innovative solutions where conventional treatments have fallen short. Proponents of psychedelic-assisted therapy have hailed the decision, citing years of promising clinical research indicating these substances can produce profound, lasting therapeutic benefits when administered in controlled, medical settings.

The directive does not legalize or reschedule any drugs but creates a streamlined pathway for rigorous federal review. It represents a notable departure from longstanding prohibitionist approaches, instead embracing a science-based framework to potentially expand the arsenal of treatments available to millions of Americans suffering from debilitating mental health conditions. Research institutions are expected to receive updated guidance to facilitate further clinical trials in the coming months.